1
|
Dubbelman MA, Tomassen J, van der Landen SM, Bakker E, Kamps S, van Unnik AAJM, van de Glind MCABJ, van der Vlies AE, Koene T, Leeuwis AE, Barkhof F, van Harten AC, Teunissen C, van de Giessen E, Lemstra AW, Pijnenburg YAL, Ponds RWH, Sikkes SAM. Visual associative learning to detect early episodic memory deficits and distinguish Alzheimer's disease from other types of dementia. J Int Neuropsychol Soc 2024; 30:584-593. [PMID: 38389489 DOI: 10.1017/s1355617724000079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/24/2024]
Abstract
OBJECTIVE We investigated how well a visual associative learning task discriminates Alzheimer's disease (AD) dementia from other types of dementia and how it relates to AD pathology. METHODS 3,599 patients (63.9 ± 8.9 years old, 41% female) from the Amsterdam Dementia Cohort completed two sets of the Visual Association Test (VAT) in a single test session and underwent magnetic resonance imaging. We performed receiver operating curve analysis to investigate the VAT's discriminatory ability between AD dementia and other diagnoses and compared it to that of other episodic memory tests. We tested associations between VAT performance and medial temporal lobe atrophy (MTA), and amyloid status (n = 2,769, 77%). RESULTS Patients with AD dementia performed worse on the VAT than all other patients. The VAT discriminated well between AD and other types of dementia (area under the curve range 0.70-0.86), better than other episodic memory tests. Six-hundred forty patients (17.8%) learned all associations on VAT-A, but not on VAT-B, and they were more likely to have higher MTA scores (odds ratios range 1.63 (MTA 0.5) through 5.13 for MTA ≥ 3, all p < .001) and to be amyloid positive (odds ratio = 3.38, 95%CI = [2.71, 4.22], p < .001) than patients who learned all associations on both sets. CONCLUSIONS Performance on the VAT, especially on a second set administered immediately after the first, discriminates AD from other types of dementia and is associated with MTA and amyloid positivity. The VAT might be a useful, simple tool to assess early episodic memory deficits in the presence of AD pathology.
Collapse
Affiliation(s)
- Mark A Dubbelman
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
- Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Jori Tomassen
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Sophie M van der Landen
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Els Bakker
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Suzie Kamps
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Annemartijn A J M van Unnik
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Marie-Christine A B J van de Glind
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Annelies E van der Vlies
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Ted Koene
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Anna E Leeuwis
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
- Old Age Psychiatry, GGZ inGeest, Amsterdam, The Netherlands
| | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands
- Institutes of Neurology and Healthcare Engineering, University College London, London, UK
| | - Argonde C van Harten
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Charlotte Teunissen
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Elsmarieke van de Giessen
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands
| | - Afina W Lemstra
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Yolande A L Pijnenburg
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
| | - Rudolf W H Ponds
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
- Department of Medical Psychology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Sietske A M Sikkes
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands
- Faculty of Behavioral and Movement Sciences, Clinical Developmental Psychology and Clinical Neuropsychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
2
|
Ciesla M, Pobst J, Gomes-Osman J, Lamar M, Barnes LL, Banks R, Jannati A, Libon D, Swenson R, Tobyne S, Bates D, Showalter J, Pascual-Leone A. Estimating dementia risk in an African American population using the DCTclock. Front Aging Neurosci 2024; 15:1328333. [PMID: 38274984 PMCID: PMC10810014 DOI: 10.3389/fnagi.2023.1328333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Accepted: 12/22/2023] [Indexed: 01/27/2024] Open
Abstract
The prevalence of Alzheimer's disease (AD) and related dementias (ADRD) is increasing. African Americans are twice as likely to develop dementia than other ethnic populations. Traditional cognitive screening solutions lack the sensitivity to independently identify individuals at risk for cognitive decline. The DCTclock is a 3-min AI-enabled adaptation of the well-established clock drawing test. The DCTclock can estimate dementia risk for both general cognitive impairment and the presence of AD pathology. Here we performed a retrospective analysis to assess the performance of the DCTclock to estimate future conversion to ADRD in African American participants from the Rush Alzheimer's Disease Research Center Minority Aging Research Study (MARS) and African American Clinical Core (AACORE). We assessed baseline DCTclock scores in 646 participants (baseline median age = 78.0 ± 6.4, median years of education = 14.0 ± 3.2, 78% female) and found significantly lower baseline DCTclock scores in those who received a dementia diagnosis within 3 years. We also found that 16.4% of participants with a baseline DCTclock score less than 60 were significantly more likely to develop dementia in 5 years vs. those with the highest DCTclock scores (75-100). This research demonstrates the DCTclock's ability to estimate the 5-year risk of developing dementia in an African American population. Early detection of elevated dementia risk using the DCTclock could provide patients, caregivers, and clinicians opportunities to plan and intervene early to improve cognitive health trajectories. Early detection of dementia risk can also enhance participant selection in clinical trials while reducing screening costs.
Collapse
Affiliation(s)
| | | | - Joyce Gomes-Osman
- Linus Health, Boston, MA, United States
- Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, United States
| | - Melissa Lamar
- Rush Alzheimer’s Disease Center, Chicago, IL, United States
- Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, United States
| | - Lisa L. Barnes
- Rush Alzheimer’s Disease Center, Chicago, IL, United States
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States
| | - Russell Banks
- Linus Health, Boston, MA, United States
- Department of Communicative Sciences and Disorders, College of Arts and Sciences, Michigan State University, East Lansing, MI, United States
| | - Ali Jannati
- Linus Health, Boston, MA, United States
- Department of Neurology, Harvard Medical School, Boston, MA, United States
| | - David Libon
- Linus Health, Boston, MA, United States
- Department of Geriatrics and Gerontology, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, United States
| | - Rodney Swenson
- Linus Health, Boston, MA, United States
- University of North Dakota School of Medicine and Health Sciences, Fargo, ND, United States
| | | | | | | | - Alvaro Pascual-Leone
- Linus Health, Boston, MA, United States
- Department of Neurology, Harvard Medical School, Boston, MA, United States
- Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife, Boston, MA, United States
| |
Collapse
|
4
|
Abdulrahman H, Richard E, van Gool WA, Moll van Charante EP, van Dalen JW. Sex Differences in the Relation Between Subjective Memory Complaints, Impairments in Instrumental Activities of Daily Living, and Risk of Dementia. J Alzheimers Dis 2021; 85:283-294. [PMID: 34806609 PMCID: PMC8842768 DOI: 10.3233/jad-215191] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
BACKGROUND Older people with subjective memory complaints (SMC) and Instrumental Activities of Daily Living impairments (IADL-I) have an increased risk of developing dementia. Previous reports suggest that the predictive value of SMC and IADL-I may differ between sexes, leaving possible consequences for personalized risk prediction and prognosis. However, none of these studies addressed the competing risk of death, which may substantially differ between sexes. OBJECTIVE We investigated sex-differences in the association between IADL-I, SMC, and incident dementia and mortality as competing risk. METHODS 3,409 community-dwelling older people without dementia (mean age 74.3±2.5), were followed for 6.7 years (median). Baseline SMC were assessed using the 15-item Geriatric Depression Scale memory question, and IADL-I using the Academic Medical Center Linear Disability Score. Potential sex-differences in the predictive value of SMC and IADL-I were assessed using Cox regression models with an interaction term for sex. RESULTS HRs for isolated SMC and SMC + IADL-I and risk of dementia were higher in women (HR: 2.02, 95% CI = 0.91-4.46, p = 0.08; HR:2.85, 95% CI = 1.65-4.91, p < 0.001) than in men (HR:1.52, 95% CI = 0.86-2.69, p = 0.18; HR:1.24, 95% CI = 0.62-2.49, p = 0.54), but these sex-differences were not significant. Conversely, HRs for isolated IADL-I and risk of mortality were higher in men (HR:1.56, 95% CI = 1.18-2.05, p = 0.002) than in women (HR:1.14, 95% CI = 0.80-1.62, p = 0.48), but again, these sex-differences were not significant. CONCLUSION The predictive value of SMC and IADL-I for the risk of dementia and mortality was not significantly modified by sex. However, the competing risk of death for these factors differed considerably between men and women, suggesting it is an essential factor to consider when comparing sex-differences in IADL/dementia risk.
Collapse
Affiliation(s)
- Herrer Abdulrahman
- Amsterdam University Medical Center, University of Amsterdam, Department of Neurology, Amsterdam, the Netherlands.,Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, the Netherlands
| | - Edo Richard
- Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, the Netherlands.,Amsterdam University Medical Center, University of Amsterdam, Department of Public and Occupational Health, Amsterdam, the Netherlands
| | - Willem A van Gool
- Amsterdam University Medical Center, University of Amsterdam, Department of Neurology, Amsterdam, the Netherlands.,Amsterdam University Medical Center, University of Amsterdam, Department of Public and Occupational Health, Amsterdam, the Netherlands
| | - Eric P Moll van Charante
- Amsterdam University Medical Center, University of Amsterdam, Department of Neurology, Amsterdam, the Netherlands.,Amsterdam University Medical Center, University of Amsterdam, Department of Public and Occupational Health, Amsterdam, the Netherlands
| | - Jan Willem van Dalen
- Amsterdam University Medical Center, University of Amsterdam, Department of Neurology, Amsterdam, the Netherlands.,Amsterdam University Medical Center, University of Amsterdam, Department of Public and Occupational Health, Amsterdam, the Netherlands
| |
Collapse
|
7
|
Licher S, Leening MJG, Yilmaz P, Wolters FJ, Heeringa J, Bindels PJE, Vernooij MW, Stephan BCM, Steyerberg EW, Ikram MK, Ikram MA. Development and Validation of a Dementia Risk Prediction Model in the General Population: An Analysis of Three Longitudinal Studies. Am J Psychiatry 2019; 176:543-551. [PMID: 30525906 DOI: 10.1176/appi.ajp.2018.18050566] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Identification of individuals at high risk of dementia is essential for development of prevention strategies, but reliable tools are lacking for risk stratification in the population. The authors developed and validated a prediction model to calculate the 10-year absolute risk of developing dementia in an aging population. METHODS In a large, prospective population-based cohort, data were collected on demographic, clinical, neuropsychological, genetic, and neuroimaging parameters from 2,710 nondemented individuals age 60 or older, examined between 1995 and 2011. A basic and an extended model were derived to predict 10-year risk of dementia while taking into account competing risks from death due to other causes. Model performance was assessed using optimism-corrected C-statistics and calibration plots, and the models were externally validated in the Dutch population-based Epidemiological Prevention Study of Zoetermeer and in the Alzheimer's Disease Neuroimaging Initiative cohort 1 (ADNI-1). RESULTS During a follow-up of 20,324 person-years, 181 participants developed dementia. A basic dementia risk model using age, history of stroke, subjective memory decline, and need for assistance with finances or medication yielded a C-statistic of 0.78 (95% CI=0.75, 0.81). Subsequently, an extended model incorporating the basic model and additional cognitive, genetic, and imaging predictors yielded a C-statistic of 0.86 (95% CI=0.83, 0.88). The models performed well in external validation cohorts from Europe and the United States. CONCLUSIONS In community-dwelling individuals, 10-year dementia risk can be accurately predicted by combining information on readily available predictors in the primary care setting. Dementia prediction can be further improved by using data on cognitive performance, genotyping, and brain imaging. These models can be used to identify individuals at high risk of dementia in the population and are able to inform trial design.
Collapse
Affiliation(s)
- Silvan Licher
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - Maarten J G Leening
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - Pinar Yilmaz
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - Frank J Wolters
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - Jan Heeringa
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - Patrick J E Bindels
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | -
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - Meike W Vernooij
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - Blossom C M Stephan
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - Ewout W Steyerberg
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - M Kamran Ikram
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| | - M Arfan Ikram
- The Department of Epidemiology (Licher, Leening, Yilmaz, Wolters, Heeringa, Vernooij, M.K. Ikram, M.A. Ikram), the Department of Neurology (Wolters, M.K. Ikram), the Department of Cardiology (Leening), the Department of Radiology and Nuclear Medicine (Yilmaz, Vernooij), and the Department of General Practice (Bindels), Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands; the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston (Leening, Wolters); the Institute of Health and Society, Newcastle University, Newcastle, U.K. (Stephan); the Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (Steyerberg); and the Center for Medical Decision Making, Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Steyerberg)
| |
Collapse
|